Irritable Bowel Syndrome Trial, Recruiting NCT05361785 Sponsor: Helsinki University Central Hospital Condition: Irritable Bowel Syndrome
Back to Irritable Bowel Syndrome

Irritable Bowel Syndrome Trial, Recruiting

NCT05361785
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 18 and 75 years old and can understand Finnish
  • You have been diagnosed with Irritable Bowel Syndrome (IBS) using a specific standard set of diagnostic criteria called Rome IV (all types of IBS are accepted)
  • You are currently using a low FODMAP diet (a specific eating plan that limits certain carbohydrates) to manage your IBS symptoms
  • You are willing and able to sign a consent form agreeing to take part in the trial

Who may not be able to join:

  • You have a diagnosed allergy to any food components included in the trial's diet plan
  • You are currently pregnant or breastfeeding
  • You have taken antibiotics within the last three months before joining the trial
  • You are unable to hold an enema (a liquid treatment given through the back passage)
  • You have a current problem with misuse of drugs, alcohol, or medications
  • You have another condition besides IBS that causes digestive symptoms, such as Inflammatory Bowel Disease (IBD), microscopic colitis, coeliac disease, or bile acid diarrhoea
  • You have a serious mental health or neurological condition that may affect your ability to follow the trial's requirements (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Perttu Arkkila, Professor, Head physician

Phone: +358504272272

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Helsinki University Central Hospital
Registry
ClinicalTrials.gov
Start date
30 April 2022
Est. completion
31 July 2024

Where this trial is recruiting

🇫🇮 Finland

Primary endpoints

The effect of FMT for tolerance of FODMAPs in the IBS patients' diet

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov